FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary Tumors.
Adult
Aged
Aged, 80 and over
Antigens, CD
/ analysis
Cadherins
/ analysis
Cell Membrane
/ metabolism
Cell Nucleus
/ metabolism
Epithelial-Mesenchymal Transition
Estrogen Receptor alpha
/ metabolism
Female
Follicle Stimulating Hormone
/ analysis
Gonadotrophs
/ cytology
Humans
Male
Middle Aged
Pituitary Neoplasms
/ blood
Retrospective Studies
E-cadherin
FSH
PitNET
pituitary adenoma
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
received:
11
03
2020
accepted:
14
05
2020
pubmed:
19
5
2020
medline:
9
2
2021
entrez:
19
5
2020
Statut:
ppublish
Résumé
Gonadotroph pituitary neuroendocrine tumors (PitNETs) can express follicle-stimulating hormone (FSH) and luteinizing hormone (LH) or be hormone negative, but they rarely secrete hormones. During tumor development, epithelial cells develop a mesenchymal phenotype. This process is characterized by decreased membranous E-cadherin and translocation of E-cadherin to the nucleus. Estrogen receptors (ERs) regulate both E-cadherin and FSH expression and secretion. Whether the hormone status of patients with gonadotroph PitNETs is regulated by epithelial-to-mesenchymal transition (EMT) and ERs is unknown. To study the effect of EMT on hormone expression in gonadotroph nonfunctioning (NF)-PitNETs. Molecular and clinical analyses of 105 gonadotroph PitNETs. Immunohistochemical studies and real-time quantitative polymerase chain reaction were performed for FSH, LH, E-cadherin, and ERα. Further analyses included blood samples, clinical data, and radiological images. All patients were operated on in the same tertiary referral center. NF-PitNET with high FSH expression had decreased immunohistochemical staining for membranous E-cadherin (P < .0001) and increased staining for nuclear E-cadherin (P < .0001). Furthermore, high FSH expression was associated with increased ERα staining (P = .0002) and ERα mRNA (P = .0039). Circulating levels of plasma-FSH (P-FSH) correlated with FSH staining in gonadotroph NF-PitNET (P = .0025). Tumor size and invasiveness was not related to FSH staining, E-cadherin, or ERα. LH expression was not associated with E-cadherin or ERα. In gonadotroph PitNETs, FSH staining is related to E-cadherin, ERα expression, and circulating levels of P-FSH. There was no association between FSH staining and invasiveness. The clinical significance of these findings will be investigated in ongoing prospective studies.
Identifiants
pubmed: 32421791
pii: 5839824
doi: 10.1210/clinem/dgaa281
pmc: PMC7758833
pii:
doi:
Substances chimiques
Antigens, CD
0
CDH1 protein, human
0
Cadherins
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Follicle Stimulating Hormone
9002-68-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Int J Surg Pathol. 2013 Aug;21(4):363-7
pubmed: 23349466
Mol Cell Endocrinol. 2016 Dec 5;437:183-189
pubmed: 27561203
J Clin Endocrinol Metab. 1994 Jun;78(6):1497-504
pubmed: 7515390
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7420-5
pubmed: 19383788
J Clin Endocrinol Metab. 2012 Aug;97(8):E1506-14
pubmed: 22585092
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
Biochim Biophys Acta. 2007 Jan;1773(1):78-88
pubmed: 17030444
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a002915
pubmed: 20182623
Cell Mol Life Sci. 2008 Nov;65(23):3756-88
pubmed: 18726070
Acta Histochem Cytochem. 2010 May 1;43(2):83-8
pubmed: 20514296
Clin Endocrinol (Oxf). 2011 Dec;75(6):811-8
pubmed: 21595730
Nature. 1998 Mar 12;392(6672):190-3
pubmed: 9515965
Neuroendocrinology. 2004 Mar;79(3):119-24
pubmed: 15103224
J Endocrinol. 2007 Jul;194(1):21-9
pubmed: 17592017
Cancer Res. 2003 Sep 1;63(17):5203-8
pubmed: 14500345
Cell Physiol Biochem. 2007;20(6):987-94
pubmed: 17982281
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11930-5
pubmed: 21730131
Cancer. 2001 Jan 1;91(1):42-8
pubmed: 11148558
J Biol Chem. 2008 May 9;283(19):12691-700
pubmed: 18356166
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3581-3590
pubmed: 28911153
Clin Endocrinol (Oxf). 2012 Jan;76(1):96-102
pubmed: 21722151
Pituitary. 2016 Aug;19(4):407-14
pubmed: 27097804
Biol Reprod. 2001 Feb;64(2):714-9
pubmed: 11159377
Nat Med. 1999 Nov;5(11):1317-21
pubmed: 10546001
Eur J Endocrinol. 2014 Oct;171(4):519-26
pubmed: 25084775
J Clin Endocrinol Metab. 1998 Nov;83(11):3965-72
pubmed: 9814476
Pathology. 2007 Jun;39(3):305-18
pubmed: 17558857
Biol Reprod. 1995 Jul;53(1):166-72
pubmed: 7545440
J Biol Chem. 2014 Sep 12;289(37):25431-44
pubmed: 25086032
J Cell Sci. 2013 Jan 15;126(Pt 2):393-401
pubmed: 23525005
Endocr Pathol. 2015 Dec;26(4):349-55
pubmed: 26481628
Diabetes. 2015 Mar;64(3):887-96
pubmed: 25277393
Endocrine. 2018 Nov;62(2):351-360
pubmed: 30051197
Cell. 2005 Dec 2;123(5):903-15
pubmed: 16325583
Oncogene. 2004 Oct 18;23(48):7947-56
pubmed: 15489912
Cell. 2003 Apr 18;113(2):207-19
pubmed: 12705869
Oncogene. 1999 Nov 25;18(50):7080-90
pubmed: 10597309
Am J Surg Pathol. 2008 Mar;32(3):413-9
pubmed: 18300809
J Clin Endocrinol Metab. 2010 Apr;95(4):1955-61
pubmed: 20133465
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6453-8
pubmed: 20308571
Oncogene. 2010 Mar 11;29(10):1451-62
pubmed: 20101232
Virchows Arch. 2012 Feb;460(2):171-81
pubmed: 22213031
Adv Anat Pathol. 2008 Jul;15(4):234-40
pubmed: 18580099
Mod Pathol. 2008 Mar;21(3):271-81
pubmed: 18084253
J Clin Endocrinol Metab. 2014 Dec;99(12):4423-33
pubmed: 25166722
Mod Pathol. 2007 Dec;20(12):1269-77
pubmed: 17873891
Cell. 2005 Dec 2;123(5):889-901
pubmed: 16325582
Mod Pathol. 2002 Dec;15(12):1357-65
pubmed: 12481018
Endocrinology. 1994 Feb;134(2):935-44
pubmed: 8299588
Mol Endocrinol. 2008 Sep;22(9):2085-98
pubmed: 18550773
J Clin Endocrinol Metab. 2011 Aug;96(8):E1237-45
pubmed: 21632819
J Clin Invest. 2002 Jan;109(2):277-83
pubmed: 11805140
Biochem Biophys Res Commun. 2015 Jun 5;461(3):525-32
pubmed: 25911324
PLoS One. 2013 Jun 25;8(6):e66927
pubmed: 23825587
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Curr Opin Genet Dev. 2006 Feb;16(1):51-9
pubmed: 16377174
Eur J Endocrinol. 2015 Nov;173(5):655-64
pubmed: 26423473
J Neuroendocrinol. 2016 Feb;28(2):12352
pubmed: 26686489
Endocrine. 2017 Jul;57(1):35-45
pubmed: 28516382
J Clin Endocrinol Metab. 2010 May;95(5):2334-42
pubmed: 20335450
J Clin Endocrinol Metab. 2009 Apr;94(4):1436-42
pubmed: 19158195
PLoS One. 2010 Oct 26;5(10):e13621
pubmed: 21049033
Neurosurgery. 2016 Dec;79(6):823-831
pubmed: 26692108
Cancer Res. 2008 Nov 1;68(21):8695-704
pubmed: 18974111